GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

Nine years after selling Medivation to Pfizer for $14 billion, David Hung, M.D., is going toe to toe with the New York ...

Despite an outcry from the biopharmaceutical industry, the U.K. government has kept the rebate rate under a national ...

Hoping to gain an edge in the rapidly growing market are MilliporeSigma and Simtra BioPharma Solutions, which have forged a ...

With great power comes great responsibility, and Insulet, accordingly, is using its influence in the diabetes management ...

Established five years ago as a first-of-its-kind manufacturer dedicated to broadening access to medicines and protecting ...

A new era of hypertension treatment is on the horizon for U.S. | The drug is the first triple-combo pill for the initial ...

As President Donald Trump vows to bridge the drug pricing gap between the U.S. and other developed countries with his “most ...

With what Insmed calls an "outstanding" phase 2 win for its treprostinil palmitil inhalation powder (TPIP) in patients with ...

Right after Robert F. Kennedy Jr. secured confirmation as U.S. | The Department of Health and Human Services has removed all ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...